Alnylam Reports Completion of Patient Enrollment in P-III APOLLO-B Study for Patisiran to Treat Transthyretin-Mediated (ATTR) Amyloidosis with Cardiomyopathy

June 2, 2021 Auto Bot Alnylam, Clinical Trials, P-III 0

Shots:

  • The company has completed the enrolment in the P-III APOLLO-B study to evaluate the efficacy & safety of patisiran vs PBO in a ratio (2:1) in 300 patients with ATTR amyloidosis with cardiomyopathy across 90 sites in 20+ countries. The results are expected in mid-2022
  • The 1EPs of the trial is the change from baseline in 6 min. walk test @12 mos. The 2EPs is to assess the efficacy on health-related QoL, mortality & cardiovascular events, cardiac biomarkers & manifestations of cardiac amyloid
  • Onpattro (Patisiran) is an RNAi therapeutic, approved in US, Canada & Japan for polyneuropathy of hATTR amyloidosis & in EU, Switzerland & Brazil for hATTR amyloidosis with Stage 1 or Stage 2 polyneuropathy

Click here to­ read full press release/ article | Ref: Businesswire | Image: Pharmaphorum

The post Alnylam Reports Completion of Patient Enrollment in P-III APOLLO-B Study for Patisiran to Treat Transthyretin-Mediated (ATTR) Amyloidosis with Cardiomyopathy first appeared on PharmaShots.